Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 8/20 | 0.56 |
| ▸ | ESR1 | P03372 | 10/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.42 |
| ▸ | TACR2 | P21452 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27798133 | 0.85 | HTR7 (0.56) | HSD17B3ESR1ESR2PTGS2PTGS1 | |
| SCHEMBL27798187 | 0.85 | HDAC3 (0.41) | HSD17B3ESR1ESR2ALDH1A1MEN1 | |
| SCHEMBL39274 | 0.85 | CES2 (0.55) | HSD17B3ESR1ESR2PTGS2ALDH1A1 | |
| SCHEMBL27819249 | 0.82 | USP5 (0.40) | HSD17B3ESR1ESR2SMN1; SMN2CYP2C9 | |
| SCHEMBL27819285 | 0.82 | ABAT (0.39) | HSD17B3ESR1ESR2LMNAADRA2A | |
| SCHEMBL8412560 | 0.78 | CES2 (0.57) | HSD17B3ESR1PTGS2 | |
| SCHEMBL7860414 | 0.77 | LMNA (0.51) | LMNACYP1A2CYP2C19SMN1; SMN2PTGS2 | |
| SCHEMBL27819250 | 0.76 | HDAC1 (0.47) | ESR1LMNASMN1; SMN2PTGS2ALDH1A1 | |
| SCHEMBL7187984 | 0.72 | HSD17B3 (0.60) | HSD17B3ESR1ESR2LMNACYP1A2 | |
| SCHEMBL420677 | 0.72 | HSD17B3 (1.00) | HSD17B3ESR1ESR2LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3340972-A1 | METHOD OF TRANSPORTING AN AGENT ACROSS BLOOD-BRAIN, BLOOD-COCHLEAR OR BLOOD-CEREBROSPINAL FLUID BARRIER | Oklahoma Medical Research Foundation (US) | 2018-07-04 | — | — | EP | claimed |
| WO-2017048778-A1 | METHOD OF TRANSPORTING AN AGENT ACROSS BLOOD-BRAIN, BLOOD-COCHLEAR OR BLOOD-CEREBROSPINAL FLUID BARRIER | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2017-03-23 | — | — | WO | claimed |
| EP-2054047-B1 | METHODS FOR TREATING ACUTE ACOUSTIC TRAUMA | HOUGH EAR INST (US) | 2014-12-17 | — | — | EP | claimed |
| US-8420595-B2 | Methods for treating acute acoustic trauma | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2013-04-16 | — | — | US | claimed |
| US-20100022458-A1 | METHODS FOR TREATING ACUTE ACOUSTIC TRAUMA | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2010-01-28 | — | — | US | claimed |
| EP-2054047-A2 | METHODS FOR TREATING ACUTE ACOUSTIC TRAUMA | Hough Ear Institute (US) | 2009-05-06 | — | — | EP | claimed |
| WO-2008013866-A2 | METHODS FOR TREATING ACUTE ACOUSTIC TRAUMA | HOUGH EAR INSTITUTE (US) | 2008-01-31 | — | — | WO | claimed |
| EP-2670403-B1 | METHODS FOR TREATING BRAIN INJURY | HOUGH EAR INST (US) | 2021-08-18 | — | — | EP | disclosed |
| US-11020354-B2 | Formulations of n-acetylcysteine and uses thereof | OTOLOGIC PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210137861-A1 | METHODS FOR REDUCING ACCUMULATED PATHOLOGIC TAU PROTEIN | HOUGH EAR INSTITUTE (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210069354-A1 | METHOD OF TRANSPORTING AN AGENT ACROSS BLOOD-BRAIN, BLOOD-COCHLEAR OR BLOOD-CEREBROSPINAL FLUID BARRIER | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2021-03-11 | — | — | US | disclosed |
| EP-3787750-A1 | METHODS FOR REDUCING ACCUMULATED PATHOLOGIC TAU PROTEIN | Hough Ear Institute (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200164021-A1 | METHODS FOR ENHANCING SYNAPTOGENESIS AND NEURITOGENESIS | HOUGH EAR INSTITUTE (US) | 2020-05-28 | — | — | US | disclosed |
| EP-2670403-A1 | METHODS FOR TREATING BRAIN INJURY | Hough Ear Institute (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8420595-B2 | Methods for treating acute acoustic trauma | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2013-04-16 | — | — | US | disclosed |
| WO-2012106654-A1 | METHODS FOR TREATING BRAIN INJURY | HOUGH EAR INSTITUTE (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20120172435-A1 | METHODS FOR TREATING ACUTE ACOUSTIC TRAUMA | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2012-07-05 | — | — | US | disclosed |
| US-20100022458-A1 | METHODS FOR TREATING ACUTE ACOUSTIC TRAUMA | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2010-01-28 | — | — | US | disclosed |
| EP-2054047-A2 | METHODS FOR TREATING ACUTE ACOUSTIC TRAUMA | Hough Ear Institute (US) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008013866-A2 | METHODS FOR TREATING ACUTE ACOUSTIC TRAUMA | HOUGH EAR INSTITUTE (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022458-A1 | METHODS FOR TREATING ACUTE ACOUSTIC TRAUMA | GSR, SLC25A20, TXN2 | HSD17B3 3411/4885ESR1 2601/4885ESR2 1906/4885 |
| US-11020354-B2 | Formulations of n-acetylcysteine and uses thereof | MGMT, GCLC, AANAT | HSD17B3 4185/4885ESR1 4733/4885ESR2 4131/4885 |
| US-20200164021-A1 | METHODS FOR ENHANCING SYNAPTOGENESIS AND NEURITOGENESIS | NLN, NCSTN, NES | HSD17B3 3050/4885ESR1 4869/4885ESR2 4611/4885 |
| US-20210137861-A1 | METHODS FOR REDUCING ACCUMULATED PATHOLOGIC TAU PROTEIN | MAPT, PRNP, PSEN2 | HSD17B3 3065/4885ESR1 4816/4885ESR2 4138/4885 |
| US-20120172435-A1 | METHODS FOR TREATING ACUTE ACOUSTIC TRAUMA | TXN2, TXN, ATF1 | HSD17B3 3154/4885ESR1 4762/4885ESR2 4134/4885 |
| US-20210069354-A1 | METHOD OF TRANSPORTING AN AGENT ACROSS BLOOD-BRAIN, BLOOD-COCHLEAR OR BLOOD-CEREBROSPINAL FLUID BARRIER | NUCB2, SPNS2, CSTB | HSD17B3 2421/4885ESR1 4623/4885ESR2 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.